KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Depreciation & Amortization (CF) (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $23.5 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 9.62% year-over-year to $23.5 million; the TTM value through Dec 2025 reached $95.8 million, down 11.95%, while the annual FY2025 figure was $95.8 million, 11.95% down from the prior year.
  • Depreciation & Amortization (CF) reached $23.5 million in Q4 2025 per EBS's latest filing, roughly flat from $23.4 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $44.5 million in Q2 2022 and bottomed at $23.4 million in Q3 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $29.8 million, with a median of $29.0 million recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 34.04% in 2022, then fell 26.07% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $29.2 million in 2021, then grew by 21.92% to $35.6 million in 2022, then decreased by 16.85% to $29.6 million in 2023, then decreased by 12.16% to $26.0 million in 2024, then decreased by 9.62% to $23.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $23.5 million in Q4 2025, $23.4 million in Q3 2025, and $23.5 million in Q2 2025.